Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Tabebuia impetiginosa (Mart. Ex DC. Mattos) Bark Extracts Inhibit the Growth Gastrointestinal Bacterial Pathogens and Potentiate the Activity of some Conventional Antibiotics

    wadmin1By wadmin1April 1, 2020Updated:August 9, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Alejandra Fernandez1,2, Ian Edwin Cock1,2,*

    1School of Environment and Science, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland, AUSTRALIA.

    2Environmental Futures Research Institute, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland, AUSTRALIA.

    Pharmacognosy Communications,2020,10,2,75-82.
    DOI:10.5530/pc.2020.2.15
    Published: April 2020
    Type: Original Article

    ABSTRACT

    Introduction: Tabebuia impetiginosa (Mart. Ex DC. Mattos) bark has been used to treat inflammation and cancer, as well as a variety of pathogenic diseases, in traditional South American healing systems. As practitioners of complementary medicine frequently use herbal medicines concurrently with conventional antibiotics, the effects of both therapies in combination needs to be evaluated. Methods: The growth inhibitory activity of T. impetiginosa bark extracts was assessed against a panel of gastrointestinal bacterial pathogens by standard disc diffusion and liquid dilution minimum inhibitory concentration (MIC) methods. Combinational effects between the extracts and conventional antimicrobials were classified using the sum of the fractional inhibitory concentration. The toxicity of the individual samples and combinations was evaluated by Artemia lethality and MTS HDF cell viability assays. Results: T. impetiginosa bark extracts strongly inhibited the growth of B. cereus but were ineffective against Escherichia coli, Shigella sonnei, Staphylococcus aureus. The mid polarity ethyl acetate extract was a particularly good inhibitor of B. cereus growth (DD and LD MIC values of 45 and 245 μg/mL respectively). However, the effects of combinations of the extracts and conventional antibiotics was of considerably more interest. Although no synergistic interactions were noted, the potency of some combinations were substantially potentiated compared to activity of the individual components. Additive potentiation was was noted for combinations containing the T. impetiginosa water extract and erythromycin, chloramphenicol or penicillin-G against E. coli and S. aureus. Combinations containing ciprofloxacin also produced additive effects against all of the bacteria tested. Therefore, these combinations have enhanced benefits over either component alone. Of further note, antagonistic interactions were also detected in several combinations containing ciprofloxacin (particularly against S. aureus). These combinations should therefore be avoided against that bacterium. Conclusion: T. impetiginosa bark extracts inhibit the growth of B. cereus when tested alone and potentiated the activity of some conventional antibiotics against a panel of gastrointestinal pathogens when used in combination. Thus, T. impetiginosa bark extracts have potential in the treatment of diarrhoea and other gastrointestinal diseases.

    Key words: Bacillus cereus, Diarrhoea, Escherichia coli, Gastrointestinal disease, Lapachol, Pau d’arco, Shigella sonnei, Staphylococcus aureau.

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up